MCM
SRPT icon

Manchester Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Manchester Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$44 Hold
2
– – ﹤0.01% 1305
2025
Q4 		$44 Hold
2
– – ﹤0.01% 1342
2025
Q3 		$39 Sell
2
-235
-99% -$4.19K ﹤0.01% 1286
2025
Q2 		$4.05K Hold
237
– – ﹤0.01% 933
2025
Q1 		$15.1K Hold
237
– – ﹤0.01% 767
2024
Q4 		$28.8K Buy
237
+110
+87% +$13.5K ﹤0.01% 655
2024
Q3 		$15.9K Hold
127
– – ﹤0.01% 722
2024
Q2 		$20.1K Buy
127
+125
+6,250% +$16.1K ﹤0.01% 658
2024
Q1 		$259 Hold
2
– – ﹤0.01% 985
2023
Q4 		$193 Sell
2
-1
-33% -$96 ﹤0.01% 976
2023
Q3 		$364 Hold
3
– – ﹤0.01% 924
2023
Q2 		$344 Buy
+3
New +$387 ﹤0.01% 905
2021
Q1 		– Sell
-3
Closed -$1K – 773
2020
Q4 		$1K Buy
+3
New +$445 ﹤0.01% 699
2019
Q2 		– Sell
-570
Closed -$68K – 635
2019
Q1 		$68K Buy
+570
New +$73.3K 0.01% 360
2014
Q2 		– Sell
-83
Closed -$2K – 1105
2014
Q1 		$2K Buy
+83
New +$2.12K ﹤0.01% 967

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Manchester Capital Management's SRPT Position: Q1 2026 in Review

Manchester Capital Management held its Sarepta Therapeutics (SRPT) position steady in Q1 2026 at 2 shares worth $44. The position accounts for ﹤0.01% of the portfolio, ranked #1305.

Manchester Capital Management first reported a position in SRPT in Q1 2014 and has held it in 15 quarters since. The position peaked at $68K in Q1 2019. 340 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Manchester Capital Management held 2 shares of Sarepta Therapeutics worth $44 as of Q1 2026.
  • Manchester Capital Management left its Sarepta Therapeutics share count unchanged in Q1 2026.
  • Sarepta Therapeutics made up ﹤0.01% of Manchester Capital Management's portfolio in Q1 2026, its #1305 holding.
  • Manchester Capital Management first reported a position in Sarepta Therapeutics in Q1 2014 and has held it in 15 quarters since.
  • Manchester Capital Management's Sarepta Therapeutics position peaked at $68K in Q1 2019.
  • 340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Manchester Capital Management's 13F filing for Q1 2026, filed 11 May 2026.